O 5: Coagulation Factors in Multiple Sclerosis may Represent Diagnostic and Therapeutic Strategies

Authors

  • Fatemeh Shahbeigi Islamic Azad University, Mashhad Branch, Mashhad, Iran
  • Hossein Feizi Islamic Azad University, Mashhad Branch, Mashhad, Iran
Abstract:

Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease which mediated by various molecular and cellular immune components However Recent reports have shown that coagulation factors that traditionally separate from the immune system might also be involved in MS development and progression.studies on experimental autoimmune encephalomyelitis (EAE) and human MS patients reports alterations of some factors of the coagulation cascade such as fibrin, thrombin, prothrombin, factor X and FXII to confirm that coagulation factors have an important role in pathogenesis of autoimmune inflammatory disorders, recent studies report that Genetic deficiency or pharmacologic blockade of FXII significantly protected from EAE and also fibrin depletion, either genetically or using anticoagulants, significantly reduces neurolinflammation, and axonal damage in EAE. Another important study shows that increase thrombin activity is an early event and increases with progression of neuroinflammatory disease, with noted microglial activation and axonal damage. In this review we aim to evaluate elevated coagulation factors of tissue or blood as a new therapeutic strategy for the treatment of MS or other neuroinflammatoy disorders. As we described some coagulation factors such as fibrin and thrombin are significantly increased in MS and blockade of this factors in EAE improve neurolinflammation, and axonal damage so maybe using anticoagulants in Clinical trials develop treatment of MS.

similar resources

o 5: coagulation factors in multiple sclerosis may represent diagnostic and therapeutic strategies

multiple sclerosis (ms) is a neuroinflammatory autoimmune disease which mediated by various molecular and cellular immune components however recent reports have shown that coagulation factors that traditionally separate from the immune system might also be involved in ms development and progression.studies on experimental autoimmune encephalomyelitis (eae) and human ms patients reports alterati...

full text

O 10: Multiple Sclerosis: General Aspects of Pathophysiology, Symptoms and Therapeutic Options

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system associated to myelin loss and neurodegeneration. Clinically patients suffer from diverse symptoms and face the risk to become wheelchair-bound. At the moment MS is incurable, thus there is an unmet need for therapeutic options. 

full text

Cell-based therapeutic strategies for multiple sclerosis

The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease. However, all are only partially effective in preventing inflammatory tissue damage in the central nervous system and none directly promotes repair. Cell-based therapies, including immunoablation followed by autologou...

full text

O9: Mechanisms and Therapeutic Options in Multiple Sclerosis

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system associated to myelin loss and neurodegeneration. Clinically patients suffer from diverse symptoms and face the risk to become wheelchair-bound. At the moment MS is incurable, thus there is an unmet need for therapeutic options.

full text

Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies

Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last dec...

full text

Multiple sclerosis--novel insights and new therapeutic strategies.

PURPOSE OF REVIEW This review focuses on novel aspects of the pathogenesis and advances in the therapy of multiple sclerosis (MS). RECENT FINDINGS Recent observations suggest that early lesion development in MS may start in some forms with oligodendrocyte death and that inflammation appears as a secondary phenomenon only. The lack of sufficient remyelination in MS may be the result of a distu...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 5  issue 2

pages  5- 5

publication date 2017-04

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023